File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Immunotherapeutic approaches in nasopharyngeal carcinoma

TitleImmunotherapeutic approaches in nasopharyngeal carcinoma
Authors
KeywordsAdoptive cell therapy
cancer vaccine
Epstein-Barr virus (EBV)
immunotherapy
monoclonal antibody
Issue Date2019
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ebt
Citation
Expert Opinion on Biological Therapy, 2019, v. 19 n. 11, p. 1165-1172 How to Cite?
AbstractIntroduction: Nasopharyngeal carcinoma (NPC) is endemic in Southern China and Southeast Asia. Epstein-Barr virus (EBV) represents a unique etiological culprit in the poorly differentiated nonkeratinizing and undifferentiated subtypes. EBV antigens are expressed on tumor cells albeit in a restricted manner. Treatment options for recurrent or metastatic disease are limited. Nevertheless, emerging data from immunotherapy studies in NPC have shed light into their potential antitumor efficacy. Areas covered: This article reviews existing clinical evidence for different immunotherapeutic approaches for NPC, including adoptive cellular therapy, therapeutic cancer vaccines, and immune checkpoint inhibitors. Expert opinion: There is a growing understanding on EBV virology and the immune evasion mechanisms in NPC. Immunotherapeutic strategies leveraging these properties have shown encouraging efficacy and safety results in early-phase clinical studies. Moving forward, areas to be addressed include appropriate patient selection, optimal incorporation into standard treatment paradigms, biomarker identification, as well as the development of scalable and reproducible immune product generation processes.
Persistent Identifierhttp://hdl.handle.net/10722/294033
ISSN
2019 Impact Factor: 3.224
2015 SCImago Journal Rankings: 1.171
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChow, JCH-
dc.contributor.authorNgan, KCR-
dc.contributor.authorCheung, KM-
dc.contributor.authorCho, WCS-
dc.date.accessioned2020-11-23T08:25:23Z-
dc.date.available2020-11-23T08:25:23Z-
dc.date.issued2019-
dc.identifier.citationExpert Opinion on Biological Therapy, 2019, v. 19 n. 11, p. 1165-1172-
dc.identifier.issn1471-2598-
dc.identifier.urihttp://hdl.handle.net/10722/294033-
dc.description.abstractIntroduction: Nasopharyngeal carcinoma (NPC) is endemic in Southern China and Southeast Asia. Epstein-Barr virus (EBV) represents a unique etiological culprit in the poorly differentiated nonkeratinizing and undifferentiated subtypes. EBV antigens are expressed on tumor cells albeit in a restricted manner. Treatment options for recurrent or metastatic disease are limited. Nevertheless, emerging data from immunotherapy studies in NPC have shed light into their potential antitumor efficacy. Areas covered: This article reviews existing clinical evidence for different immunotherapeutic approaches for NPC, including adoptive cellular therapy, therapeutic cancer vaccines, and immune checkpoint inhibitors. Expert opinion: There is a growing understanding on EBV virology and the immune evasion mechanisms in NPC. Immunotherapeutic strategies leveraging these properties have shown encouraging efficacy and safety results in early-phase clinical studies. Moving forward, areas to be addressed include appropriate patient selection, optimal incorporation into standard treatment paradigms, biomarker identification, as well as the development of scalable and reproducible immune product generation processes.-
dc.languageeng-
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ebt-
dc.relation.ispartofExpert Opinion on Biological Therapy-
dc.rightsExpert Opinion on Biological Therapy. Copyright © Informa Healthcare.-
dc.rightsThis is an electronic version of an article published in [include the complete citation information for the final version of the article as published in the print edition of the journal]. [JOURNAL TITLE] is available online at: http://www.informaworld.com/smpp/ with the open URL of your article.-
dc.subjectAdoptive cell therapy-
dc.subjectcancer vaccine-
dc.subjectEpstein-Barr virus (EBV)-
dc.subjectimmunotherapy-
dc.subjectmonoclonal antibody-
dc.titleImmunotherapeutic approaches in nasopharyngeal carcinoma-
dc.typeArticle-
dc.identifier.emailNgan, KCR: rkcngan@hku.hk-
dc.identifier.authorityNgan, KCR=rp02371-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/14712598.2019.1650910-
dc.identifier.pmid31361154-
dc.identifier.scopuseid_2-s2.0-85070902178-
dc.identifier.hkuros319710-
dc.identifier.volume19-
dc.identifier.issue11-
dc.identifier.spage1165-
dc.identifier.epage1172-
dc.identifier.isiWOS:000480953300001-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl1471-2598-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats